patent Archives -

In a dramatic change in fortunes, Novartis has won a major victory in its bid to defend oral

Supreme court throws Novartis a lifeline for Gilenya defense

https://pharmaphorum.com/news/supreme-court-throws-novartis-a-lifeline-for-gilenya-defense/

News/ News/ Sales and Marketing

Novartis knocked back again in bid to block Gilenya generics in US

Phil Taylor Gilenya, HEC Pharma, litigation, multiple sclerosis, Novartis, patent 0 Comment

Novartis is running out of options in its bid to defend oral muscular sclerosis therapy Gilenya from early

Novartis knocked back again in bid to block Gilenya generics in US

https://pharmaphorum.com/news/novartis-knocked-back-again-in-bid-to-block-gilenya-generics-in-us/

News/ News/ Sales and Marketing

Novartis probed by Swiss authorities over ‘unlawful’ patent use

Phil Taylor antitrust, EU, Financial, Novartis, patent, regulatory, switzerland 0 Comment

The competition authorities in Switzerland said this morning they have carried out a raid on a pharma company

Novartis probed by Swiss authorities over ‘unlawful’ patent use

https://pharmaphorum.com/news/novartis-probed-by-swiss-authorities-over-unlawful-patent-use/

News/ News/ Sales and Marketing

Moderna sues Pfizer/BioNTech over COVID-19 vaccine tech

Phil Taylor BioNTech, coronavirus, COVID-19, COVID-19 vaccine, litigation, Moderna, patent, Pfizer 0 Comment

The rivalry between Moderna and Pfizer/BioNTech in commercialising their COVID-19 vaccines has now spilled over into the courts,

Moderna sues Pfizer/BioNTech over COVID-19 vaccine tech

https://pharmaphorum.com/news/moderna-sues-pfizer-biontech-over-covid-19-vaccine-tech/

News/ News/ Sales and Marketing

ViiV claims $1.25bn settlement from Gilead in HIV patent dispute

Phil Taylor Biktarvy, Gilead Sciences, GlaxoSmithKline, HIV, patent, patent litigation, ViiV Healthcare 0 Comment

A patent dispute between ViiV Healthcare and Gilead Sciences has been resolved, with Gilead agreeing to pay a

ViiV claims $1.25bn settlement from Gilead in HIV patent dispute

https://pharmaphorum.com/news/viiv-claims-1-25bn-settlement-from-gilead-in-hiv-patent-dispute/

News/ News/ Sales and Marketing

Appeals court reverses $1.2bn judgment against Gilead in BMS CAR-T case

Phil Taylor Bristol-Myers Squibb, CAR-T therapies, Gilead Sciences, Juno Therapeutics, Kite Pharma, litigation, patent 0 Comment

Gilead Sciences’ Kite Pharma has won a key victory on appeal in its long-running dispute with Bristol Myers

Appeals court reverses $1.2bn judgment against Gilead in BMS CAR-T case

https://pharmaphorum.com/news/appeals-court-reverses-1-2bn-judgment-against-gilead-in-bms-car-t-case/

Market Access/ News/ News

Alvotech files lawsuit challenging AbbVie’s Humira patent thicket

Richard Staines AbbVie, Alvotech, biosimilars, Humira, inflammatory diseases, patent 0 Comment

Biosimilars firm Alvotech has filed a lawsuit that challenges AbbVie’s legal defences surrounding the inflammatory disease drug Humira

Alvotech files lawsuit challenging AbbVie’s Humira patent thicket

https://pharmaphorum.com/news/alvotech-files-lawsuit-challenging-abbvies-humira-patent-thicket/

Market Access/ News/ News

Pfizer shares slump as support grows for COVID-19 vaccine patent waiver

Richard Staines COVID-19, patent, Pfizer, vaccine 0 Comment

Shares in COVID-19 vaccine manufacturers have taken a hit after the US signalled its support for waiving patents

Pfizer shares slump as support grows for COVID-19 vaccine patent waiver

https://pharmaphorum.com/news/pfizer-shares-slump-as-support-grows-for-covid-19-vaccine-patent-waiver/

Market Access/ News/ News

Teva faces EU antitrust probe over MS drug Copaxone

Richard Staines Copaxone, multiple sclerosis, patent, Teva 0 Comment

The European Commission has formally opened an antitrust investigation into Teva, which will assess whether the pharma company

Teva faces EU antitrust probe over MS drug Copaxone

https://pharmaphorum.com/news/teva-faces-eu-antitrust-probe-over-ms-drug-copaxone/

Trending

patent

Login